FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2773791657> ?p ?o ?g. }

• W2773791657 endingPage "551" @default.
• W2773791657 startingPage "541" @default.
• W2773791657 abstract "Background Type 2 diabetes is a chronic disorder that requires lifelong treatment. We aimed to assess whether intensive weight management within routine primary care would achieve remission of type 2 diabetes. Methods We did this open-label, cluster-randomised trial (DiRECT) at 49 primary care practices in Scotland and the Tyneside region of England. Practices were randomly assigned (1:1), via a computer-generated list, to provide either a weight management programme (intervention) or best-practice care by guidelines (control), with stratification for study site (Tyneside or Scotland) and practice list size (>5700 or ≤5700). Participants, carers, and research assistants who collected outcome data were aware of group allocation; however, allocation was concealed from the study statistician. We recruited individuals aged 20–65 years who had been diagnosed with type 2 diabetes within the past 6 years, had a body-mass index of 27–45 kg/m2, and were not receiving insulin. The intervention comprised withdrawal of antidiabetic and antihypertensive drugs, total diet replacement (825–853 kcal/day formula diet for 3–5 months), stepped food reintroduction (2–8 weeks), and structured support for long-term weight loss maintenance. Co-primary outcomes were weight loss of 15 kg or more, and remission of diabetes, defined as glycated haemoglobin (HbA1c) of less than 6·5% (<48 mmol/mol) after at least 2 months off all antidiabetic medications, from baseline to 12 months. These outcomes were analysed hierarchically. This trial is registered with the ISRCTN registry, number 03267836. Findings Between July 25, 2014, and Aug 5, 2017, we recruited 306 individuals from 49 intervention (n=23) and control (n=26) general practices; 149 participants per group comprised the intention-to-treat population. At 12 months, we recorded weight loss of 15 kg or more in 36 (24%) participants in the intervention group and no participants in the control group (p<0·0001). Diabetes remission was achieved in 68 (46%) participants in the intervention group and six (4%) participants in the control group (odds ratio 19·7, 95% CI 7·8–49·8; p<0·0001). Remission varied with weight loss in the whole study population, with achievement in none of 76 participants who gained weight, six (7%) of 89 participants who maintained 0–5 kg weight loss, 19 (34%) of 56 participants with 5–10 kg loss, 16 (57%) of 28 participants with 10–15 kg loss, and 31 (86%) of 36 participants who lost 15 kg or more. Mean bodyweight fell by 10·0 kg (SD 8·0) in the intervention group and 1·0 kg (3·7) in the control group (adjusted difference −8·8 kg, 95% CI −10·3 to −7·3; p<0·0001). Quality of life, as measured by the EuroQol 5 Dimensions visual analogue scale, improved by 7·2 points (SD 21·3) in the intervention group, and decreased by 2·9 points (15·5) in the control group (adjusted difference 6·4 points, 95% CI 2·5–10·3; p=0·0012). Nine serious adverse events were reported by seven (4%) of 157 participants in the intervention group and two were reported by two (1%) participants in the control group. Two serious adverse events (biliary colic and abdominal pain), occurring in the same participant, were deemed potentially related to the intervention. No serious adverse events led to withdrawal from the study. Interpretation Our findings show that, at 12 months, almost half of participants achieved remission to a non-diabetic state and off antidiabetic drugs. Remission of type 2 diabetes is a practical target for primary care. Funding Diabetes UK. Type 2 diabetes is a chronic disorder that requires lifelong treatment. We aimed to assess whether intensive weight management within routine primary care would achieve remission of type 2 diabetes. We did this open-label, cluster-randomised trial (DiRECT) at 49 primary care practices in Scotland and the Tyneside region of England. Practices were randomly assigned (1:1), via a computer-generated list, to provide either a weight management programme (intervention) or best-practice care by guidelines (control), with stratification for study site (Tyneside or Scotland) and practice list size (>5700 or ≤5700). Participants, carers, and research assistants who collected outcome data were aware of group allocation; however, allocation was concealed from the study statistician. We recruited individuals aged 20–65 years who had been diagnosed with type 2 diabetes within the past 6 years, had a body-mass index of 27–45 kg/m2, and were not receiving insulin. The intervention comprised withdrawal of antidiabetic and antihypertensive drugs, total diet replacement (825–853 kcal/day formula diet for 3–5 months), stepped food reintroduction (2–8 weeks), and structured support for long-term weight loss maintenance. Co-primary outcomes were weight loss of 15 kg or more, and remission of diabetes, defined as glycated haemoglobin (HbA1c) of less than 6·5% (<48 mmol/mol) after at least 2 months off all antidiabetic medications, from baseline to 12 months. These outcomes were analysed hierarchically. This trial is registered with the ISRCTN registry, number 03267836. Between July 25, 2014, and Aug 5, 2017, we recruited 306 individuals from 49 intervention (n=23) and control (n=26) general practices; 149 participants per group comprised the intention-to-treat population. At 12 months, we recorded weight loss of 15 kg or more in 36 (24%) participants in the intervention group and no participants in the control group (p<0·0001). Diabetes remission was achieved in 68 (46%) participants in the intervention group and six (4%) participants in the control group (odds ratio 19·7, 95% CI 7·8–49·8; p<0·0001). Remission varied with weight loss in the whole study population, with achievement in none of 76 participants who gained weight, six (7%) of 89 participants who maintained 0–5 kg weight loss, 19 (34%) of 56 participants with 5–10 kg loss, 16 (57%) of 28 participants with 10–15 kg loss, and 31 (86%) of 36 participants who lost 15 kg or more. Mean bodyweight fell by 10·0 kg (SD 8·0) in the intervention group and 1·0 kg (3·7) in the control group (adjusted difference −8·8 kg, 95% CI −10·3 to −7·3; p<0·0001). Quality of life, as measured by the EuroQol 5 Dimensions visual analogue scale, improved by 7·2 points (SD 21·3) in the intervention group, and decreased by 2·9 points (15·5) in the control group (adjusted difference 6·4 points, 95% CI 2·5–10·3; p=0·0012). Nine serious adverse events were reported by seven (4%) of 157 participants in the intervention group and two were reported by two (1%) participants in the control group. Two serious adverse events (biliary colic and abdominal pain), occurring in the same participant, were deemed potentially related to the intervention. No serious adverse events led to withdrawal from the study. Our findings show that, at 12 months, almost half of participants achieved remission to a non-diabetic state and off antidiabetic drugs. Remission of type 2 diabetes is a practical target for primary care." @default.
• W2773791657 created "2017-12-22" @default.
• W2773791657 creator A5005567532 @default.
• W2773791657 creator A5010325069 @default.
• W2773791657 creator A5010469897 @default.
• W2773791657 creator A5012241596 @default.
• W2773791657 creator A5016068379 @default.
• W2773791657 creator A5016095791 @default.
• W2773791657 creator A5018377905 @default.
• W2773791657 creator A5031039790 @default.
• W2773791657 creator A5032843256 @default.
• W2773791657 creator A5035551614 @default.
• W2773791657 creator A5037322796 @default.
• W2773791657 creator A5038313768 @default.
• W2773791657 creator A5039342849 @default.
• W2773791657 creator A5040022046 @default.
• W2773791657 creator A5041787533 @default.
• W2773791657 creator A5054370506 @default.
• W2773791657 creator A5059393492 @default.
• W2773791657 creator A5063872643 @default.
• W2773791657 creator A5066907505 @default.
• W2773791657 creator A5075086360 @default.
• W2773791657 creator A5075866018 @default.
• W2773791657 creator A5078354802 @default.
• W2773791657 creator A5078498803 @default.
• W2773791657 creator A5079248131 @default.
• W2773791657 creator A5081145530 @default.
• W2773791657 date "2018-02-01" @default.
• W2773791657 modified "2023-10-18" @default.
• W2773791657 title "Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial" @default.
• W2773791657 cites W1970727299 @default.
• W2773791657 cites W1975801154 @default.
• W2773791657 cites W2027524238 @default.
• W2773791657 cites W2033918682 @default.
• W2773791657 cites W2043473227 @default.
• W2773791657 cites W2051682994 @default.
• W2773791657 cites W2051785784 @default.
• W2773791657 cites W2058782323 @default.
• W2773791657 cites W2059838547 @default.
• W2773791657 cites W2061574308 @default.
• W2773791657 cites W2089342771 @default.
• W2773791657 cites W2110392605 @default.
• W2773791657 cites W2127283831 @default.
• W2773791657 cites W2147307613 @default.
• W2773791657 cites W2160489098 @default.
• W2773791657 cites W2171294019 @default.
• W2773791657 cites W2180429985 @default.
• W2773791657 cites W2196045865 @default.
• W2773791657 cites W2282195952 @default.
• W2773791657 cites W2535658226 @default.
• W2773791657 cites W2567007802 @default.
• W2773791657 cites W2581264645 @default.
• W2773791657 cites W2584016859 @default.
• W2773791657 cites W2738645055 @default.
• W2773791657 cites W2755949111 @default.
• W2773791657 cites W2766919801 @default.
• W2773791657 cites W4234995814 @default.
• W2773791657 doi "https://doi.org/10.1016/s0140-6736(17)33102-1" @default.
• W2773791657 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29221645" @default.
• W2773791657 hasPublicationYear "2018" @default.
• W2773791657 type Work @default.
• W2773791657 sameAs 2773791657 @default.
• W2773791657 citedByCount "1126" @default.
• W2773791657 countsByYear W27737916572017 @default.
• W2773791657 countsByYear W27737916572018 @default.
• W2773791657 countsByYear W27737916572019 @default.
• W2773791657 countsByYear W27737916572020 @default.
• W2773791657 countsByYear W27737916572021 @default.
• W2773791657 countsByYear W27737916572022 @default.
• W2773791657 countsByYear W27737916572023 @default.
• W2773791657 crossrefType "journal-article" @default.
• W2773791657 hasAuthorship W2773791657A5005567532 @default.
• W2773791657 hasAuthorship W2773791657A5010325069 @default.
• W2773791657 hasAuthorship W2773791657A5010469897 @default.
• W2773791657 hasAuthorship W2773791657A5012241596 @default.
• W2773791657 hasAuthorship W2773791657A5016068379 @default.
• W2773791657 hasAuthorship W2773791657A5016095791 @default.
• W2773791657 hasAuthorship W2773791657A5018377905 @default.
• W2773791657 hasAuthorship W2773791657A5031039790 @default.
• W2773791657 hasAuthorship W2773791657A5032843256 @default.
• W2773791657 hasAuthorship W2773791657A5035551614 @default.
• W2773791657 hasAuthorship W2773791657A5037322796 @default.
• W2773791657 hasAuthorship W2773791657A5038313768 @default.
• W2773791657 hasAuthorship W2773791657A5039342849 @default.
• W2773791657 hasAuthorship W2773791657A5040022046 @default.
• W2773791657 hasAuthorship W2773791657A5041787533 @default.
• W2773791657 hasAuthorship W2773791657A5054370506 @default.
• W2773791657 hasAuthorship W2773791657A5059393492 @default.
• W2773791657 hasAuthorship W2773791657A5063872643 @default.
• W2773791657 hasAuthorship W2773791657A5066907505 @default.
• W2773791657 hasAuthorship W2773791657A5075086360 @default.
• W2773791657 hasAuthorship W2773791657A5075866018 @default.
• W2773791657 hasAuthorship W2773791657A5078354802 @default.
• W2773791657 hasAuthorship W2773791657A5078498803 @default.
• W2773791657 hasAuthorship W2773791657A5079248131 @default.
• W2773791657 hasAuthorship W2773791657A5081145530 @default.
• W2773791657 hasBestOaLocation W27737916572 @default.
• W2773791657 hasConcept C126322002 @default.

• next